CHD1 and prostate cancer: For example, loss of CHD1 and ZNF292 occurs at a later stage in ERG-positive tumors than in ERG fusion–negative tumors, but as these lesions are common to both progression pathways, these genes seem to be key drivers of prostate cancer progression.